Public Private Partnerships: Advance rational drug repositioning and combination therapy (Milestone 14.J)
Convene an advisory meeting of experts from the pharmaceutical industry, government, academia, the FDA, and the non-profit sector to advance rational drug repositioning and combination therapy based on translational bioinformatics and network pharmacology approaches and to explore opportunities for new public-private partnerships to facilitate drug rescue/repurposing and combination therapy.
Success Criteria
-
Development of recommendations for rational repositioning and combination therapy development.
-
Development, negotiation, and implementation of appropriate agreements among the stakeholders involved in repositioning and combination therapy of drugs for AD and related dementias.
-
These agreements should address legal issues, intellectual property rights, and liability to expedite rigorous clinical testing of repurposed drugs.
Summary of Key Accomplishments
Milestone goals are supported by the proceedings of the NIH Alzheimer’s Research Summits 2015, 2018 and 2021. Each of these Summits delivered a series of research recommendations related to the advancement of data-driven drug repurposing and combination therapy development. These recommendations led to the launch of a targeted funding initiative: “Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for AD/ADRD.”
The key accomplishments summary is current as of July 2022.
- Research Implementation Area
- Public Private Partnerships
- Timeline
- 2016–2024
- Status
- In Progress